Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
First Claim
1. A method of treating leukemia or myeloma comprising administering to a patient in need thereof a proteasome inhibitor and administering to the patient a glucocorticoid receptor (GR) agonist, wherein the proteasome inhibitor is administered before, concurrently with, or after the GR agonist is administered.
2 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are methods and pharmaceutical compositions for treating diseases, disorders, and conditions associated with glucocorticoid receptor (GR) expression and activity. The disclosed methods typically include administering to a patient in need thereof a proteasome inhibitor and administering to the patient in need thereof a glucocorticoid receptor (GR) agonist, either before, concurrently with, or after the proteasome inhibitor is administered.
15 Citations
20 Claims
- 1. A method of treating leukemia or myeloma comprising administering to a patient in need thereof a proteasome inhibitor and administering to the patient a glucocorticoid receptor (GR) agonist, wherein the proteasome inhibitor is administered before, concurrently with, or after the GR agonist is administered.
- 13. A method of treating myeloma comprising administering to a patient in need thereof a proteasome inhibitor and a selective GR agonist (SEGRA) to the patient.
Specification